AKEBIA THERAPEUTICS, INC. Cash and Restricted Cash
AKEBIA THERAPEUTICS, INC. (AKBA) had Cash and Restricted Cash of $157.26 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $157.26M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $164.35M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $186.54M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $168.14M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $157.26M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $164.35M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $186.54M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $168.14M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $139.00M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $115.06M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $53.55M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $35.69M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $41.17M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $43.62M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $44.58M 10-K · filed 2026-02-26 |
| 2023-09-30 | $48.18M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $55.29M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $59.66M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $93.17M 10-K · filed 2026-02-26 |
| 2022-09-30 | $147.85M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $146.98M 10-Q · filed 2023-08-28 |
| 2022-03-31 | $177.65M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $151.84M 10-K · filed 2024-03-14 |
| 2021-09-30 | $209.24M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $249.03M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $254.80M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $231.13M 10-K/A · filed 2023-08-28 |
| 2020-09-30 | $171.72M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $247.84M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $117.81M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $149.80M 10-K/A · filed 2023-08-28 |
| 2019-09-30 | $125.24M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $89.67M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $65.20M 10-Q · filed 2020-05-05 |
| 2018-12-31 | $107.10M 10-K · filed 2022-03-01 |
| 2018-09-30 | $164.00M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $165.09M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $159.45M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $71.44M 10-K · filed 2021-02-25 |
| 2017-09-30 | $90.88M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $126.67M 10-Q · filed 2018-08-08 |
| 2017-03-31 | $88.53M 10-Q · filed 2018-05-09 |
| 2016-12-31 | $188.62M 10-K · filed 2020-03-12 |
| 2015-12-31 | $51.06M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |